Share Price and Basic Stock Data
Last Updated: December 5, 2025, 5:57 pm
| PEG Ratio | 3.49 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Bafna Pharmaceuticals Ltd operates in the dynamic pharmaceutical sector, where it has shown a mixed performance in recent years. The company’s revenue trajectory has been quite volatile, with sales reported at ₹115 Cr in FY 2023, which slightly declined to ₹146 Cr in FY 2025. This fluctuating pattern is evident in quarterly figures as well; for instance, sales peaked at ₹42.24 Cr in March 2023 but saw a decline to ₹28.44 Cr by December 2023. Such inconsistencies can raise eyebrows among potential investors, especially when considering the overall growth trajectory in the pharmaceutical sector, which has been buoyed by heightened healthcare demands post-pandemic. Moreover, Bafna’s revenue growth over the past few quarters suggests a certain level of resilience, with quarterly sales stabilizing around ₹40 Cr in mid-2023. However, this performance needs to be contextualized against industry benchmarks to ascertain whether it is keeping pace with sectoral growth.
Profitability and Efficiency Metrics
When examining profitability, Bafna Pharmaceuticals reported an operating profit margin (OPM) of 14.64% in FY 2025, which is respectable, particularly in a sector where margins can be tight. However, this figure has fluctuated significantly over the years, peaking as high as 18.04% in March 2023 before dipping to lower levels in subsequent quarters. The net profit for the same fiscal year stood at ₹4 Cr, indicating a positive yet modest return on equity of 7.69%. This suggests that while the company is generating profit, the return relative to shareholder equity is on the lower side, particularly in a sector that often commands higher returns. Efficiency metrics also show room for improvement; the cash conversion cycle (CCC) is recorded at 88 days, which, while manageable, indicates that capital is tied up for extended periods. Bafna’s interest coverage ratio of 15.48 times, however, appears strong, suggesting that the company is comfortably managing its interest expenses.
Balance Sheet Strength and Financial Ratios
Bafna Pharmaceuticals’ balance sheet reflects a cautious approach, with total borrowings reported at ₹32 Cr against reserves of ₹68 Cr. This translates to a debt-to-equity ratio that seems manageable, although the company’s P/BV ratio of -0.49x raises questions about how the market is valuing its assets. The negative figure suggests that the stock might be undervalued or that there are significant concerns about the company’s future profitability. The company has shown a consistent ability to cover its interest obligations, which is a positive sign for creditors and investors alike. However, the relatively low return on capital employed (ROCE) of 8.34% indicates that while the company is generating profits, it may not be utilizing its capital as effectively as possible. This is a critical area for Bafna to address, especially as competition in the pharmaceutical industry intensifies.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bafna Pharmaceuticals reveals a concentrated ownership structure, with promoters holding 75% of the company. This level of promoter commitment can be a double-edged sword; while it may instill confidence, it also raises concerns about the lack of diversification among shareholders. Notably, the foreign institutional investors (FIIs) have increased their stake to 9.34%, which is a promising sign of growing interest from external investors. On the flip side, domestic institutional investors (DIIs) have not shown significant participation, which could indicate a lack of confidence in the company’s long-term growth prospects. The total number of shareholders, which stood at 7,572, suggests a stable base, but the recent decline in public shareholding from 16.47% to 15.66% may point to potential concerns regarding liquidity or investor sentiment.
Outlook, Risks, and Final Insight
Looking ahead, Bafna Pharmaceuticals faces several risks and opportunities that could influence its performance. The volatility in revenue and profit margins raises questions about the sustainability of its growth strategy. While the company has a solid interest coverage ratio, the low ROE and fluctuating OPM highlight the need for strategic initiatives to enhance profitability. Additionally, the competitive landscape in the pharmaceutical sector, coupled with regulatory challenges, could pose significant risks. Investors should also consider the implications of a concentrated shareholding pattern, as this could affect decision-making and corporate governance. In summary, while Bafna Pharmaceuticals has shown resilience, potential investors should weigh the company’s strengths against its risks, keeping an eye on its ability to stabilize revenue and improve efficiency metrics to enhance shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bafna Pharmaceuticals Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,110 Cr. | 377 | 479/192 | 85.1 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,585.22 Cr | 1,173.27 | 52.01 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 16.93 | 21.96 | 34.22 | 42.24 | 41.95 | 40.68 | 28.44 | 41.40 | 33.29 | 40.32 | 33.19 | 39.06 | 34.62 |
| Expenses | 15.27 | 19.42 | 31.18 | 34.62 | 35.66 | 36.67 | 30.51 | 38.51 | 32.08 | 36.53 | 30.13 | 35.95 | 29.55 |
| Operating Profit | 1.66 | 2.54 | 3.04 | 7.62 | 6.29 | 4.01 | -2.07 | 2.89 | 1.21 | 3.79 | 3.06 | 3.11 | 5.07 |
| OPM % | 9.81% | 11.57% | 8.88% | 18.04% | 14.99% | 9.86% | -7.28% | 6.98% | 3.63% | 9.40% | 9.22% | 7.96% | 14.64% |
| Other Income | 1.30 | 0.64 | 1.93 | 0.26 | 1.87 | 0.16 | 0.98 | 0.52 | 0.16 | 1.02 | 0.18 | -0.76 | 0.60 |
| Interest | 0.31 | 0.45 | 0.58 | 0.70 | 0.60 | 0.44 | 0.58 | 0.68 | 0.65 | 0.62 | 0.64 | 0.82 | 0.91 |
| Depreciation | 1.29 | 1.12 | 1.40 | 1.53 | 1.21 | 1.24 | 1.27 | 1.27 | 1.44 | 1.58 | 1.66 | 0.22 | 1.37 |
| Profit before tax | 1.36 | 1.61 | 2.99 | 5.65 | 6.35 | 2.49 | -2.94 | 1.46 | -0.72 | 2.61 | 0.94 | 1.31 | 3.39 |
| Tax % | -0.00% | -0.00% | -0.00% | 4.96% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Net Profit | 1.36 | 1.61 | 3.00 | 5.37 | 6.35 | 2.48 | -2.94 | 1.46 | -0.72 | 2.62 | 0.95 | 1.31 | 3.39 |
| EPS in Rs | 0.57 | 0.68 | 1.27 | 2.27 | 2.68 | 1.05 | -1.24 | 0.62 | -0.30 | 1.11 | 0.40 | 0.55 | 1.43 |
Last Updated: August 20, 2025, 1:15 pm
Below is a detailed analysis of the quarterly data for Bafna Pharmaceuticals Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 34.62 Cr.. The value appears to be declining and may need further review. It has decreased from 39.06 Cr. (Mar 2025) to 34.62 Cr., marking a decrease of 4.44 Cr..
- For Expenses, as of Jun 2025, the value is 29.55 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 35.95 Cr. (Mar 2025) to 29.55 Cr., marking a decrease of 6.40 Cr..
- For Operating Profit, as of Jun 2025, the value is 5.07 Cr.. The value appears strong and on an upward trend. It has increased from 3.11 Cr. (Mar 2025) to 5.07 Cr., marking an increase of 1.96 Cr..
- For OPM %, as of Jun 2025, the value is 14.64%. The value appears strong and on an upward trend. It has increased from 7.96% (Mar 2025) to 14.64%, marking an increase of 6.68%.
- For Other Income, as of Jun 2025, the value is 0.60 Cr.. The value appears strong and on an upward trend. It has increased from -0.76 Cr. (Mar 2025) to 0.60 Cr., marking an increase of 1.36 Cr..
- For Interest, as of Jun 2025, the value is 0.91 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.82 Cr. (Mar 2025) to 0.91 Cr., marking an increase of 0.09 Cr..
- For Depreciation, as of Jun 2025, the value is 1.37 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.22 Cr. (Mar 2025) to 1.37 Cr., marking an increase of 1.15 Cr..
- For Profit before tax, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 2.08 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 3.39 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 3.39 Cr., marking an increase of 2.08 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.43. The value appears strong and on an upward trend. It has increased from 0.55 (Mar 2025) to 1.43, marking an increase of 0.88.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:26 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 177 | 100 | 85 | 65 | 46 | 44 | 42 | 71 | 85 | 115 | 152 | 146 | 147 |
| Expenses | 156 | 116 | 82 | 70 | 81 | 57 | 41 | 61 | 73 | 100 | 141 | 135 | 132 |
| Operating Profit | 21 | -16 | 3 | -5 | -35 | -13 | 1 | 10 | 12 | 16 | 11 | 11 | 15 |
| OPM % | 12% | -16% | 3% | -8% | -77% | -30% | 3% | 14% | 14% | 14% | 7% | 8% | 10% |
| Other Income | 1 | 40 | 1 | 1 | 31 | 0 | -23 | 1 | -0 | 3 | 4 | 1 | 1 |
| Interest | 12 | 12 | 12 | 11 | 7 | 2 | 0 | 1 | 1 | 2 | 2 | 3 | 3 |
| Depreciation | 8 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 2 | 6 | -13 | -19 | -14 | -18 | -25 | 6 | 5 | 12 | 7 | 4 | 8 |
| Tax % | 40% | -0% | -3% | -4% | 15% | 8% | 0% | 0% | 0% | 2% | 0% | 0% | |
| Net Profit | 1 | 6 | -12 | -18 | -16 | -20 | -25 | 6 | 5 | 11 | 7 | 4 | 8 |
| EPS in Rs | 0.72 | 3.28 | -6.53 | -9.90 | -6.95 | -8.34 | -106.53 | 2.46 | 2.21 | 4.79 | 3.11 | 1.75 | 3.49 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 500.00% | -300.00% | -50.00% | 11.11% | -25.00% | -25.00% | 124.00% | -16.67% | 120.00% | -36.36% | -42.86% |
| Change in YoY Net Profit Growth (%) | 0.00% | -800.00% | 250.00% | 61.11% | -36.11% | 0.00% | 149.00% | -140.67% | 136.67% | -156.36% | -6.49% |
Bafna Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 28% |
| 3 Years: | 20% |
| TTM: | 2% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 40% |
| 3 Years: | -5% |
| TTM: | 1498% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 34% |
| 3 Years: | -4% |
| 1 Year: | 25% |
| Return on Equity | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| Last Year: | 8% |
Last Updated: September 5, 2025, 12:15 am
Balance Sheet
Last Updated: December 4, 2025, 1:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 19 | 24 | 24 | 2 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 50 | 53 | 41 | 26 | 17 | -3 | 49 | 33 | 38 | 50 | 57 | 61 | 68 |
| Borrowings | 99 | 64 | 80 | 82 | 47 | 46 | 3 | 15 | 11 | 23 | 24 | 28 | 32 |
| Other Liabilities | 54 | 50 | 45 | 40 | 40 | 54 | 17 | 14 | 17 | 33 | 42 | 40 | 37 |
| Total Liabilities | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 161 |
| Fixed Assets | 63 | 49 | 47 | 43 | 40 | 37 | 35 | 36 | 39 | 40 | 40 | 59 | 65 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 12 | 7 | 15 |
| Investments | 1 | 18 | 18 | 18 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 158 | 118 | 120 | 106 | 86 | 82 | 36 | 50 | 51 | 88 | 95 | 87 | 81 |
| Total Assets | 223 | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 161 |
Below is a detailed analysis of the balance sheet data for Bafna Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 24.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 24.00 Cr..
- For Reserves, as of Sep 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 61.00 Cr. (Mar 2025) to 68.00 Cr., marking an increase of 7.00 Cr..
- For Borrowings, as of Sep 2025, the value is 32.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 28.00 Cr. (Mar 2025) to 32.00 Cr., marking an increase of 4.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 37.00 Cr.. The value appears to be improving (decreasing). It has decreased from 40.00 Cr. (Mar 2025) to 37.00 Cr., marking a decrease of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 161.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 153.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 8.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 65.00 Cr.. The value appears strong and on an upward trend. It has increased from 59.00 Cr. (Mar 2025) to 65.00 Cr., marking an increase of 6.00 Cr..
- For CWIP, as of Sep 2025, the value is 15.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 15.00 Cr., marking an increase of 8.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 81.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Mar 2025) to 81.00 Cr., marking a decrease of 6.00 Cr..
- For Total Assets, as of Sep 2025, the value is 161.00 Cr.. The value appears strong and on an upward trend. It has increased from 153.00 Cr. (Mar 2025) to 161.00 Cr., marking an increase of 8.00 Cr..
Notably, the Reserves (68.00 Cr.) exceed the Borrowings (32.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -78.00 | -80.00 | -77.00 | -87.00 | -82.00 | -59.00 | -2.00 | -5.00 | 1.00 | -7.00 | -13.00 | -17.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 192 | 303 | 291 | 302 | 195 | 208 | 52 | 49 | 63 | 130 | 109 | 101 |
| Inventory Days | 78 | 66 | 92 | 118 | 102 | 122 | 208 | 154 | 185 | 129 | 125 | 127 |
| Days Payable | 116 | 149 | 169 | 164 | 265 | 517 | 229 | 107 | 113 | 165 | 149 | 140 |
| Cash Conversion Cycle | 155 | 220 | 214 | 255 | 31 | -188 | 31 | 96 | 135 | 94 | 84 | 88 |
| Working Capital Days | 41 | 56 | 125 | -36 | -108 | -210 | 89 | 121 | 123 | 104 | 92 | 74 |
| ROCE % | 9% | -13% | -0% | -6% | -35% | -21% | -3% | 10% | 11% | 16% | 9% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Diluted EPS (Rs.) | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Cash EPS (Rs.) | -89.52 | -6.29 | -5.47 | -8.17 | -5.51 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 |
| Revenue From Operations / Share (Rs.) | 179.54 | 18.33 | 19.94 | 34.82 | 45.73 |
| PBDIT / Share (Rs.) | 6.25 | -5.36 | -1.61 | -2.50 | 1.34 |
| PBIT / Share (Rs.) | -7.56 | -6.83 | -3.29 | -4.76 | -1.27 |
| PBT / Share (Rs.) | -103.32 | -7.30 | -6.22 | -10.91 | -8.21 |
| Net Profit / Share (Rs.) | -103.32 | -7.76 | -7.15 | -10.43 | -8.12 |
| NP After MI And SOA / Share (Rs.) | -104.54 | -7.98 | -7.07 | -10.23 | -7.52 |
| PBDIT Margin (%) | 3.48 | -29.26 | -8.05 | -7.18 | 2.92 |
| PBIT Margin (%) | -4.20 | -37.28 | -16.47 | -13.68 | -2.76 |
| PBT Margin (%) | -57.54 | -39.86 | -31.19 | -31.34 | -17.95 |
| Net Profit Margin (%) | -57.54 | -42.32 | -35.84 | -29.95 | -17.74 |
| NP After MI And SOA Margin (%) | -58.22 | -43.52 | -35.48 | -29.38 | -16.44 |
| Return on Networth / Equity (%) | 0.00 | -99.01 | -44.12 | -44.73 | -24.28 |
| Return on Capital Employeed (%) | -3.29 | -33.22 | -9.90 | -9.17 | -2.41 |
| Return On Assets (%) | -34.67 | -15.79 | -12.09 | -10.70 | -7.27 |
| Long Term Debt / Equity (X) | -0.71 | 1.21 | 0.61 | 0.91 | 0.60 |
| Total Debt / Equity (X) | -0.71 | 2.43 | 1.23 | 1.93 | 1.39 |
| Asset Turnover Ratio (%) | 0.44 | 0.33 | 0.30 | 0.36 | 0.44 |
| Current Ratio (X) | 2.11 | 0.68 | 0.81 | 0.94 | 1.29 |
| Quick Ratio (X) | 1.44 | 0.55 | 0.63 | 0.74 | 1.11 |
| Inventory Turnover Ratio (X) | 2.24 | 2.66 | 1.55 | 0.89 | 0.97 |
| Interest Coverage Ratio (X) | 15.48 | -5.97 | -0.54 | -0.40 | 0.19 |
| Interest Coverage Ratio (Post Tax) (X) | -18.72 | -8.10 | -1.44 | -0.69 | -0.16 |
| Enterprise Value (Cr.) | -3.29 | 69.21 | 109.10 | 134.30 | 133.55 |
| EV / Net Operating Revenue (X) | -0.07 | 1.60 | 2.31 | 2.07 | 1.57 |
| EV / EBITDA (X) | -2.22 | -5.45 | -28.71 | -28.76 | 53.52 |
| MarketCap / Net Operating Revenue (X) | 0.04 | 0.59 | 1.40 | 0.84 | 0.65 |
| Price / BV (X) | -0.49 | 1.36 | 1.75 | 1.29 | 0.96 |
| Price / Net Operating Revenue (X) | 0.04 | 0.59 | 1.40 | 0.84 | 0.65 |
| EarningsYield | -11.80 | -0.72 | -0.25 | -0.34 | -0.25 |
After reviewing the key financial ratios for Bafna Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 20, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 19) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
- For Diluted EPS (Rs.), as of Mar 20, the value is -15.52. This value is below the healthy minimum of 5. It has decreased from -11.48 (Mar 19) to -15.52, marking a decrease of 4.04.
- For Cash EPS (Rs.), as of Mar 20, the value is -89.52. This value is below the healthy minimum of 3. It has decreased from -6.29 (Mar 19) to -89.52, marking a decrease of 83.23.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 20, the value is -17.59. It has decreased from 7.97 (Mar 19) to -17.59, marking a decrease of 25.56.
- For Revenue From Operations / Share (Rs.), as of Mar 20, the value is 179.54. It has increased from 18.33 (Mar 19) to 179.54, marking an increase of 161.21.
- For PBDIT / Share (Rs.), as of Mar 20, the value is 6.25. This value is within the healthy range. It has increased from -5.36 (Mar 19) to 6.25, marking an increase of 11.61.
- For PBIT / Share (Rs.), as of Mar 20, the value is -7.56. This value is below the healthy minimum of 0. It has decreased from -6.83 (Mar 19) to -7.56, marking a decrease of 0.73.
- For PBT / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 0. It has decreased from -7.30 (Mar 19) to -103.32, marking a decrease of 96.02.
- For Net Profit / Share (Rs.), as of Mar 20, the value is -103.32. This value is below the healthy minimum of 2. It has decreased from -7.76 (Mar 19) to -103.32, marking a decrease of 95.56.
- For NP After MI And SOA / Share (Rs.), as of Mar 20, the value is -104.54. This value is below the healthy minimum of 2. It has decreased from -7.98 (Mar 19) to -104.54, marking a decrease of 96.56.
- For PBDIT Margin (%), as of Mar 20, the value is 3.48. This value is below the healthy minimum of 10. It has increased from -29.26 (Mar 19) to 3.48, marking an increase of 32.74.
- For PBIT Margin (%), as of Mar 20, the value is -4.20. This value is below the healthy minimum of 10. It has increased from -37.28 (Mar 19) to -4.20, marking an increase of 33.08.
- For PBT Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 10. It has decreased from -39.86 (Mar 19) to -57.54, marking a decrease of 17.68.
- For Net Profit Margin (%), as of Mar 20, the value is -57.54. This value is below the healthy minimum of 5. It has decreased from -42.32 (Mar 19) to -57.54, marking a decrease of 15.22.
- For NP After MI And SOA Margin (%), as of Mar 20, the value is -58.22. This value is below the healthy minimum of 8. It has decreased from -43.52 (Mar 19) to -58.22, marking a decrease of 14.70.
- For Return on Networth / Equity (%), as of Mar 20, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -99.01 (Mar 19) to 0.00, marking an increase of 99.01.
- For Return on Capital Employeed (%), as of Mar 20, the value is -3.29. This value is below the healthy minimum of 10. It has increased from -33.22 (Mar 19) to -3.29, marking an increase of 29.93.
- For Return On Assets (%), as of Mar 20, the value is -34.67. This value is below the healthy minimum of 5. It has decreased from -15.79 (Mar 19) to -34.67, marking a decrease of 18.88.
- For Long Term Debt / Equity (X), as of Mar 20, the value is -0.71. This value is below the healthy minimum of 0.2. It has decreased from 1.21 (Mar 19) to -0.71, marking a decrease of 1.92.
- For Total Debt / Equity (X), as of Mar 20, the value is -0.71. This value is within the healthy range. It has decreased from 2.43 (Mar 19) to -0.71, marking a decrease of 3.14.
- For Asset Turnover Ratio (%), as of Mar 20, the value is 0.44. It has increased from 0.33 (Mar 19) to 0.44, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 20, the value is 2.11. This value is within the healthy range. It has increased from 0.68 (Mar 19) to 2.11, marking an increase of 1.43.
- For Quick Ratio (X), as of Mar 20, the value is 1.44. This value is within the healthy range. It has increased from 0.55 (Mar 19) to 1.44, marking an increase of 0.89.
- For Inventory Turnover Ratio (X), as of Mar 20, the value is 2.24. This value is below the healthy minimum of 4. It has decreased from 2.66 (Mar 19) to 2.24, marking a decrease of 0.42.
- For Interest Coverage Ratio (X), as of Mar 20, the value is 15.48. This value is within the healthy range. It has increased from -5.97 (Mar 19) to 15.48, marking an increase of 21.45.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 20, the value is -18.72. This value is below the healthy minimum of 3. It has decreased from -8.10 (Mar 19) to -18.72, marking a decrease of 10.62.
- For Enterprise Value (Cr.), as of Mar 20, the value is -3.29. It has decreased from 69.21 (Mar 19) to -3.29, marking a decrease of 72.50.
- For EV / Net Operating Revenue (X), as of Mar 20, the value is -0.07. This value is below the healthy minimum of 1. It has decreased from 1.60 (Mar 19) to -0.07, marking a decrease of 1.67.
- For EV / EBITDA (X), as of Mar 20, the value is -2.22. This value is below the healthy minimum of 5. It has increased from -5.45 (Mar 19) to -2.22, marking an increase of 3.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
- For Price / BV (X), as of Mar 20, the value is -0.49. This value is below the healthy minimum of 1. It has decreased from 1.36 (Mar 19) to -0.49, marking a decrease of 1.85.
- For Price / Net Operating Revenue (X), as of Mar 20, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.59 (Mar 19) to 0.04, marking a decrease of 0.55.
- For EarningsYield, as of Mar 20, the value is -11.80. This value is below the healthy minimum of 5. It has decreased from -0.72 (Mar 19) to -11.80, marking a decrease of 11.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bafna Pharmaceuticals Ltd:
- Net Profit Margin: -57.54%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -3.29% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -18.72
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.44
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 33.4 (Industry average Stock P/E: 52.01)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.71
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -57.54%
Fundamental Analysis of Bafna Pharmaceuticals Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Bafna Towers, New�No.�68,�Old�No. 299,�� � Chennai (Madras) Tamil Nadu 600001 | cs@bafnapharma.com http://www.bafnapharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. S Hemalatha | Chairperson & Executive Director |
| Mrs. Akila C Raju | Non Exe.Non Ind.Director |
| Ms. R Chitra | Ind. Non-Executive Director |
| Mr. B Kamlesh Kumar | Ind. Non-Executive Director |
| Mr. P K Sundaresan | Ind. Non-Executive Director |
Bafna Pharmaceuticals Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹94.77 |
| Previous Day | ₹99.75 |
FAQ
What is the intrinsic value of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd's intrinsic value (as of 05 December 2025) is 80.90 which is 45.70% lower the current market price of 149.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 353 Cr. market cap, FY2025-2026 high/low of 205/67.8, reserves of ₹68 Cr, and liabilities of 161 Cr.
What is the Market Cap of Bafna Pharmaceuticals Ltd?
The Market Cap of Bafna Pharmaceuticals Ltd is 353 Cr..
What is the current Stock Price of Bafna Pharmaceuticals Ltd as on 05 December 2025?
The current stock price of Bafna Pharmaceuticals Ltd as on 05 December 2025 is 149.
What is the High / Low of Bafna Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bafna Pharmaceuticals Ltd stocks is 205/67.8.
What is the Stock P/E of Bafna Pharmaceuticals Ltd?
The Stock P/E of Bafna Pharmaceuticals Ltd is 33.4.
What is the Book Value of Bafna Pharmaceuticals Ltd?
The Book Value of Bafna Pharmaceuticals Ltd is 38.6.
What is the Dividend Yield of Bafna Pharmaceuticals Ltd?
The Dividend Yield of Bafna Pharmaceuticals Ltd is 0.00 %.
What is the ROCE of Bafna Pharmaceuticals Ltd?
The ROCE of Bafna Pharmaceuticals Ltd is 8.34 %.
What is the ROE of Bafna Pharmaceuticals Ltd?
The ROE of Bafna Pharmaceuticals Ltd is 7.69 %.
What is the Face Value of Bafna Pharmaceuticals Ltd?
The Face Value of Bafna Pharmaceuticals Ltd is 10.0.